Skip to content

Welcome to Discover Pharma! Today is : November 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Discovery & Development

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference

    FundaMental Pharma GmbH will present new preclinical data on its [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oncoinvent to present 24-month Phase 1 ovarian cancer data for Radspherin at ESGO 2026

    Oncoinvent will present final 24-month follow-up data from its Phase [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development

    Scribe Therapeutics secures milestone $1.5BN collaboration with Eli Lilly for in vivo CRISPR program

    Scribe Therapeutics has achieved a second success milestone in its [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Insilico Medicine and CMS announce AI-powered drug discovery collaborations in CNS and autoimmune diseases

    Insilico Medicine and China Medical System Holdings Limited (CMS) have [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Genomics and sequencing

    New England Biolabs launches Monarch Mag Cell-free DNA extraction kit for scalable cfDNA isolation

    New England Biolabs has launched the Monarch Mag Cell-free DNA [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Nucleome Therapeutics appoints Michelle Morrow as chief scientific officer

    Nucleome Therapeutics has appointed Michelle Morrow as chief scientific officer, [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia

    Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Positive Phase 3 KALOS and LOGOS trial results for Breztri published in The Lancet Respiratory Medicine

    Full results from the Phase 3 KALOS and LOGOS trials [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Evogene and Shanghai Lishan Biopharmaceuticals enter exclusive licensing agreement for BMC128

    Evogene Ltd and Shanghai Lishan Biopharmaceuticals Co. have entered into [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    AmacaThera named Life Sciences Ontario emerging company of the year

    AmacaThera has been named Emerging Company of the Year by [...]

    May 5, 2026
Previous272829Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Biogen’s felzartamab approved in China for multiple myeloma
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
  • Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • CEPI funds Minapharm’s Phase 1 Bundibugyo Ebola vaccine programme
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top